Progress in Drug Delivery Systems Based on Nanoparticles for Improved Glioblastoma Therapy: Addressing Challenges and Investigating Opportunities
Cancers · 19.02.2025 · 17 (4) · 701
DOI: 10.3390/cancers17040701 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 19.02.2025. Verfasst von Md Ataur Rahman und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA. Die Arbeit wurde bisher 78-mal zitiert (Crossref) und nennt 192 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Scientific Research at Imam Mohammad Ibn Saud Islamic University (IMSIU).
Abstract (Originalsprache)
Glioblastoma multiforme (GBM) is a highly malignant brain tumor that has a bleak outlook despite existing treatments such as surgery, radiation, and chemotherapy. The utilization of nanoparticles for drug delivery presents a promising method by which to improve the effectiveness of treatment while reducing the harmful effects on the entire body. This review examines the application of nanoparticles in the treatment of GBM, focusing on different types of nanoparticles, including lipid-based, polymeric, metallic, and those under development. Every variety is analyzed for its distinct characteristics and therapeutic capacity. Lipid-based nanoparticles, such as liposomes and solid lipid nanoparticles, enhance the transport of medicines that are not soluble in water and have shown considerable potential in preclinical investigations. Polymeric nanoparticles have benefits in terms of controlled release and targeted distribution, whereas metallic nanoparticles have potential in both therapy and imaging. In the current review we would like to emphasize the ways in which nanoparticles improve medicine delivery, specifically by enhancing penetration of the blood–brain barrier (BBB), targeting tumors, and enabling controlled release. Additionally, we also discuss current preclinical and clinical discoveries, highlighting both achievements and obstacles in the process of converting these technologies into effective treatments for GBM. This study offers a thorough examination of the present status and prospects of nanoparticles in the treatment of GBM.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA.
- Department of Biology, College of Science, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh 11623, Saudi Arabia.
ORCID-Profile: Md Ataur Rahman
Förderung
- Scientific Research at Imam Mohammad Ibn Saud Islamic University (IMSIU)
Zitieren
APA
Rahman, M. A., Jalouli, M., Yadab, M. K., & Al-Zharani, M. (2025). Progress in Drug Delivery Systems Based on Nanoparticles for Improved Glioblastoma Therapy: Addressing Challenges and Investigating Opportunities. Cancers, 17(4), 701. https://doi.org/10.3390/cancers17040701
Vancouver
Rahman MA, Jalouli M, Yadab MK, Al-Zharani M. Progress in Drug Delivery Systems Based on Nanoparticles for Improved Glioblastoma Therapy: Addressing Challenges and Investigating Opportunities. Cancers. 2025;17(4):701. doi:10.3390/cancers17040701
BibTeX
@article{Rahman2025,
author = {Rahman, Md Ataur and Jalouli, Maroua and Yadab, Mahesh Kumar and Al-Zharani, Mohammed},
title = {Progress in Drug Delivery Systems Based on Nanoparticles for Improved Glioblastoma Therapy: Addressing Challenges and Investigating Opportunities},
journal = {Cancers},
year = {2025},
volume = {17},
number = {4},
pages = {701},
doi = {10.3390/cancers17040701}
}
EUVIMED